The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Zenas BioPharma secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback